---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-008267"
form_type: "8-K"
ticker: "MPLT"
cik: "0001770069"
company_name: "MapLight Therapeutics, Inc."
filed_at: "2026-01-09T23:59:59+00:00"
generated_at: "2026-05-16T11:04:49.362988+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MapLight reports $450M cash; Phase 2 ZEPHYR & IRIS topline results now expected Q3 2026

## Summary
- Preliminary cash and equivalents ~$450M as of Dec 31, 2025.
- Phase 2 ZEPHYR trial for schizophrenia topline results expected Q3 2026; enrollment ahead of schedule.
- Phase 2 IRIS trial for autism spectrum disorder completed enrollment; topline results also Q3 2026.
- ZEPHYR is a 300-patient randomized double-blind placebo-controlled trial for acute psychosis.
- IRIS trial randomized ~160 adult and adolescent participants with autism spectrum disorder.

## SEC filing metadata
- accession: 0001193125-26-008267
- form_type: 8-K
- ticker: MPLT
- cik: 0001770069
- company_name: MapLight Therapeutics, Inc.
- filed_at: 2026-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770069/000119312526008267/0001193125-26-008267-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770069/000119312526008267/mplt-20260109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-008267
- JSON: https://secwatch.observer/filing/0001193125-26-008267.json
- Plain text: https://secwatch.observer/filing/0001193125-26-008267.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.